Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Androgen deprivation therapy, primarily via a gonadotropin-releasing hormone receptor agonist or antagonist together with or without an androgen receptor antagonist, remains the mainstay of medical treatment for advanced prostate cancer. Meanwhile, relugolix has been developed as the first orally ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatenuma, Tomoyuki, Miyamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408655/
https://www.ncbi.nlm.nih.gov/pubmed/37559910
http://dx.doi.org/10.2147/DDDT.S373546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408655/
https://www.ncbi.nlm.nih.gov/pubmed/37559910
http://dx.doi.org/10.2147/DDDT.S373546

Ejemplares similares